Tencent Invests in NeoWise Bio, a Pioneer in Solid Tumor TCR-T Cell Therapy

People's Finance News, February 2nd: According to the Qichacha APP, recently, Neowise Biotechnology (Suzhou) Co., Ltd. underwent industrial and commercial changes, adding Guangxi Tencent Venture Investment Co., Ltd. as shareholders, while its registered capital increased to 7.7922 million yuan. Qichacha information shows that the company was established in 2020, with a business scope including pharmaceutical production; technical services, technical development, technical consultation, technical exchange, technical transfer, and technology promotion; medical research and experimental development. According to its official website, the company is an innovative enterprise focusing on developing TCR-T immunotherapy drugs for solid tumors, researching clinical technologies, and conducting translational research.